摘要:目的  考察普通肝素、低分子肝素和磺达肝癸钠治疗冠脉综合征的效果差异。方法  将120例急性冠脉综合征患者随机分为A、B、C三组，每组40例。A组患者给予肝素治疗、B组患者给予低分子肝素治疗、C组患者给予磺达肝癸钠治疗。比较三组患者治疗9d和30d主要疗效终点（主要不良心血管事件）和出血（主要出血和轻微出血）发生率差异。结果  治疗9d时三组患者主要疗效终点无显著差异，治疗30d时C组患者心肌梗死发生率显著低于A、B两组（P<0.05）。治疗9d时三组患者主要出血和轻微出血发生率无显著差异（P>0.05），治疗30d时B、C两组患者主要出血和轻微出血发生率均低于A组患者（P<0.01,P<0.05），B、C两组间无统计学差异（P>0.05）。结论  磺达肝癸钠治疗冠脉综合征的疗效更佳且更为安全，具有临床应用价值。

Abstract: Objective To investigate the difference clinical effects of unfractionated heparin, LMWH and fondaparinux in treatment of coronary syndrome. Methods 120 cases of patients with acute coronary syndrome were randomly divided into A, B, C three groups, 40 cases in each group. Group A was treated with heparin, group B were treated with low molecular weight heparin, and group C were treated with fondaparinux. The difference of endpoint primary treatment efficacy including major adverse cardiovascular events and bleeding in patients at 9 and 30 days between the three groups were analyzed. Results The main endpoint treatment effects at 9 days between three groups had no significant difference. The incidence of myocardial infarction in Group C at 30 days after treatment was significantly lower than that of group A and group B (P<0.05). The main and minor bleeding incidence rate in Group B and group C at 30 days after treatment were lower than that of patients in group A (P<0.01), but there was no significant difference between group B and group C (P>0.05). Conclusion The treatment efficacy of fondaparinux in coronary syndrome and is more safe, and might have clinical application value.